Phaseline

Companies › FutureChem

FutureChem: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 3; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[177-Lu]Ludotadipep
Lutetium-177 labeled PSMA-targeting peptide radiopharmaceutical
–Phase 3Prostate CancerMar 2028
[F-18]Florastamin
Radiopharmaceutical PET/CT imaging agent
–Phase 3High Risk Prostate Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05004285[F-18]FlorastaminPhase 3High Risk Prostate CarcinomaOncologyJun 2025
NCT05936658[F-18]FlorastaminPhase 3High Risk Prostate CarcinomaOncologyJun 2025
NCT07853209[177-Lu]LudotadipepPhase 3Prostate CancerOncologyMar 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Curium US Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.